Forte Biosciences, Inc. (FBRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3060 PEGASUS PARK DRIVE
DALLAS, TX 75247
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:41,10042,04458,76521,80096,10088,725
Cash and cash equivalents41,10042,04458,7658,98640,81335,933
Short-term investments    12,83555,27352,792
Other undisclosed cash, cash equivalents, and short-term investments    (21)14 
Prepaid expense411476545   
Other undisclosed current assets  5881,1561,6481,904
Total current assets:41,51142,52059,89822,95697,74890,629
Noncurrent Assets
Operating lease, right-of-use asset    3,515
Property, plant and equipment  971,6893,9731,217
Other noncurrent assets4867861,244 1,360227
Total noncurrent assets:4867861,3415,2045,3331,444
TOTAL ASSETS:41,99743,30661,23928,160103,08192,073
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,1791,7582,2598,46016,49810,071
Accounts payable1,1539461,2403,2183,4041,951
Accrued liabilities2,0268121,0195,24213,0948,120
Debt    4,744 7,200
Deferred revenue and credits36
Other undisclosed current liabilities     3623
Total current liabilities:3,1791,7582,25913,20416,53417,330
Noncurrent Liabilities
Long-term debt and lease obligation    4,02726,2013,625
Long-term debt, excluding current maturities     26,2013,625
Liabilities, other than long-term debt    812,20136
Deferred revenue and credits36
Deferred rent credit     2,201
Other liabilities    81  
Operating lease, liability    4,027
Total noncurrent liabilities:    4,10828,4023,661
Total liabilities:3,1791,7582,25917,31244,93620,991
Equity
Equity, attributable to parent38,81841,54858,98010,84858,14571,082
Common stock211513232320
Additional paid in capital125,841114,698110,424290,215274,029238,025
Accumulated other comprehensive income (loss)   10(23)(34)
Accumulated deficit(87,044)(73,165)(51,457)(279,400)(215,884)(166,929)
Total equity:38,81841,54858,98010,84858,14571,082
TOTAL LIABILITIES AND EQUITY:41,99743,30661,23928,160103,08192,073

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues    3618,03641
Revenue, net41
Gross profit:    3618,03641
Operating expenses(13,896)(21,486)(46,282)(61,547)(63,889)(37,670)
Operating loss:(13,896)(21,486)(46,282)(61,511)(45,853)(37,629)
Nonoperating income (expense)17(222)(205)  (1,300)
Other nonoperating income (expense)17(222)(205)   
Interest and debt expense    (3,820)(2,937)(1,932)
Loss from continuing operations before equity method investments, income taxes:(13,879)(21,708)(46,487)(65,331)(48,790)(40,861)
Other undisclosed income from continuing operations before income taxes    1,8161,534 
Loss from continuing operations before income taxes:(13,879)(21,708)(46,487)(63,515)(47,256)(40,861)
Income tax expense    (1)(1,699) 
Loss from continuing operations:(13,879)(21,708)(46,487)(63,516)(48,955)(40,861)
Loss before gain (loss) on sale of properties:(21,708)(46,487)(63,516)(48,955)(40,861)
Net loss:(13,879)(21,708)(46,487)(63,516)(48,955)(40,861)
Other undisclosed net income attributable to parent      1,932
Net loss available to common stockholders, diluted:(13,879)(21,708)(46,487)(63,516)(48,955)(38,929)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(13,879)(21,708)(46,487)(63,516)(48,955)(40,861)
Other comprehensive income (loss)    3311(34)
Comprehensive loss:(13,879)(21,708)(46,487)(63,483)(48,944)(40,895)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent     1,932
Comprehensive loss, net of tax, attributable to parent:(13,879)(21,708)(46,487)(63,483)(48,944)(38,963)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: